Fifth Third Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Fifth Third Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Sell	2,168 -302	-12%	-$206K	0.04%	257
2026 Q1	$1.91M	Buy	2,470 +820	+50%	+$628K	0.06%	191
2025 Q4	$1.27M	Buy	1,650 +89	+6%	+$60.4K	0.04%	222
2025 Q3	$878K	Buy	1,561 +50	+3%	+$28.3K	0.03%	261
2025 Q2	$793K	Buy	1,511 +154	+11%	+$86K	0.03%	277
2025 Q1	$861K	Buy	1,357 +258	+23%	+$177K	0.04%	241
2024 Q4	$783K	Buy	1,099 +595	+118%	+$499K	0.04%	243
2024 Q3	$530K	Buy	504 +107	+27%	+$119K	0.03%	294
2024 Q2	$417K	Buy	397 +172	+76%	+$167K	0.03%	313
2024 Q1	$217K	Buy	+225	New	+$214K	0.03%	231

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Fifth Third Wealth Advisors's REGN Position: Q2 2026 in Review

Fifth Third Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $206K and leaving 2,168 shares worth $1.35M. The position accounts for 0.04% of the portfolio, ranked #257.

Fifth Third Wealth Advisors first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.91M in Q1 2026. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Fifth Third Wealth Advisors held 2,168 shares of Regeneron Pharmaceuticals worth $1.35M as of Q2 2026.
Fifth Third Wealth Advisors sold 302 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $206K.
Regeneron Pharmaceuticals made up 0.04% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #257 holding.
Fifth Third Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Fifth Third Wealth Advisors's Regeneron Pharmaceuticals position peaked at $1.91M in Q1 2026.
334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.